Manufacturing

The new facility, to be located in Boston, MA, will contain experimental and analytical equipment for viral vector and advanced therapy process development and will expand the CDMO’s manufacturing capacity.

Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.

Pharmaceutical Technology interviewed Cloudleaf about trends in tracking vaccines through the supply chain.

The companies have entered into an agreement to support the formulation and fill/finish of Moderna’s COVID-19 vaccine supply outside of the United States.

Part of Operation Warp Speed, the trial will enroll 30,000 people ages 18 to 64 and 65 and older at 115 sites.

Biopharma looks to deliver on COVID-19 vaccines and other promising therapies.

Essential bio/pharma employees show hard work and dedication can pay off for patients.

Demand for specific advanced laboratory skills drives creates a positive employment market.

Consider a matrix of factors when choosing what type of cleanroom facility to construct.

As the first wave of mRNA vaccines are distributed, efforts will be needed to protect data and prevent errors.

Shutting down the COVID-19 pandemic requires a global, selfless effort.

Cytiva’s new facility in Shrewsbury, MA will make equipment such as single-use bioreactors.

Administration of the COVID-19 vaccination from Oxford University and AstraZeneca is expected to begin in the UK in early 2021.

The virtual manufacturer and distributor of specialty materials acquired the NY-based company, adding analytical and manufacturing expertise.

The UK company is investing £3 million in new instrumentation and equipment to strengthen its high-throughput screening and translational oncology service offerings.

Moderna’s mRNA vaccine to prevent COVID-19 disease is granted FDA Emergency Use Authorization and CDC recommendation.

A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.

The product represents a first-of-its-kind intentional genomic alteration in a line of domestic pigs that may be used for human therapeutics.

The company has formed an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s COVID-19 vaccine candidate, to the people of Singapore.

The HERALD trial will involve participants 18 years and older who will receive a two-dose schedule of CVnCoV or placebo at multiple sites is Europe and Latin America.

The company will expand its clinical supply chain services by establishing two new facilities in Rheinfelden and Weil am Rhein, Germany.

Freezers, shipping containers, and tracking systems aid distribution of COVID-19 vaccines.

Flexible packaging benefits align with challenges including an aging population, compliance requirements, e-commerce, serialization, and a need for recyclability.

The company will expand the site to include six new containment isolators and a product development manufacturing laboratory.

Evonik offers lipid nanoparticles for gene-based drug development and manufacturing.